Gene Therapy of Glioblastoma: Anti – Gene Anti IGF-I Strategy

Trojan, Jerzy

doi:10.5772/18129

Cited by 1 publication

(1 citation statement)

References 94 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Significant changes have been observed through this treatment, such as an increase in apoptosis and a decrease in the tumor growth, as well as an increased percentage of immune cells. Moreover, prolongation in survival time was observed and no unusual side effects were noted after the treatment [90][91][92][93][94][95][96] . These results are promising and may encourage further research using IGF-I as a therapeutic target for glioblastoma.…”

Section: Insulin-like Growth Factor-i (Igf-i)mentioning

confidence: 99%

Growth factors and kinases in glioblastoma growth

Peña-Ortiz¹,

Germán-Castelán²,

González-Arenas³

2016

Adv Mod Oncol Res

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer, having the highest invasion, migration, proliferation, and angiogenesis rates. Several signaling pathways are involved in the regulation of these processes including growth factors and their tyrosine kinase receptors, such as vascular endothelial growth factor (VEGF), transforming growth factor beta (TGFβ), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and insulin-like growth factor-I (IGF-I). Different kinases and regulators also participate in signaling pathways initiated by growth factors, such as mitogen-activated kinases (MAPK), protein kinases C (PKC), phosphatidylinositol-3 kinases (PI3K), protein kinase B (PKB or Akt), glycogen synthase kinase 3β (GSK3β), the mTOR complex, and Bcl-2. In this review, we will focus on the role of these proteins as possible therapeutic targets in GBM.

show abstract